Izvorni znanstveni članak

Observational Study on Tolerability, Efficacy and Patient Compliance during the Carvetrend® (Carvedilol) Therapy

Omer Perva ; Centar za srčane bolesti, Sarajevo
Sanko Pandur ; Klinika za kardiokirurgiju KCU Sarajevo
Katica Šantić ; Privatna kardiološka ordinacija, Široki Brijeg
Mehmed Kulić ; Centar za srčane bolesti, Sarajevo
Karmen Walaszek ; PLIVA Hrvatska d.o.o., Zagreb
Edhem Rustempašić ; PLIVA Hrvatska d.o.o., Sarajevo

Sažetak

Introduction and objectives: The primary objectives of this study were to investigate tolerability, efficacy and patient compliance during the carvedilol (Carvetrend®) therapy of arterial hypertension, coronary heart disease and congestive heart failure in outpatient setting. Patients and methods: The study was designed as an open, multicenter, non-comparative, observational phase IV study and included 183 adult patients of both genders. Out of 183 analyzed patients, 37 (20.2%) were hypertensive, 73 (39.9%) were coronary patients and 73 (39.9%) were patients with congestive heart failure. The observational period was 56.1 ± 16.9 days, during which patients attended 3 visits. Patients received the carvedilol therapy according to the dosing regimen stated in the approved patient leaflet. Tolerability and patient compliance were assessed by the investigator during the final visit. Results and conclusions: Tolerability was assessed in 152 patients; as very good in 143 patients (94%), and as good in 9 patients (6%). Patient compliance was assessed in 169 patients; as very good in 149 patients (88%), as good in 19 patients (11%), and as bad in 1 patient (1%). Therapeutic efficacy was determined over the observational period by a reduction in systolic and diastolic arterial pressure values (p < 0.001) in patients with hypertension and coronary heart disease. Data were statistically analyzed by the SAS® Stat software (SAS® System, License No. 0092661001). Carvedilol is an effective antihypertensive medication, providing statistically significant reduction in systolic and diastolic arterial pressure values in hypertensive patients treated over a short observational period (p < 0.001). Furthermore, carvedilol reduced symptoms and signs of coronary ischemic heart disease and congestive heart failure in observed patients. Carvedilol shows a favorable tolerability profile used either as a monotherapy or in combination with other medicines. Similar efficacy and tolerability of the carvedilol therapy were observed in both diabetic and nondiabetic patients. In addition, patients showed very good compliance with the carvedilol therapy.

Ključne riječi

carvedilol; arterial hypertension; coronary heart disease; congestive heart failure; tolerability; compliance; efficacy

Hrčak ID:

57581

URI

https://hrcak.srce.hr/57581

Datum izdavanja:

20.7.2009.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.229 *